Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry V Rubinstein

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
JCO Precision Oncology|February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1ENeal Akhave, Zihe Song, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1FSenthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
JCO Precision Oncology|December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol VLilian T Gien, Zihe Song, Andrew Poklepovic, et al.
JCO Precision Oncology|July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol AScott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Cancer Chemotherapy and Pharmacology|May 29, 2025
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Larry V Rubinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
JCO Precision Oncology|January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol HApril K S Salama, Victoria Wang, Erin R Macrae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
JCO Precision Oncology|February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1ENeal Akhave, Zihe Song, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1FSenthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
JCO Precision Oncology|December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol VLilian T Gien, Zihe Song, Andrew Poklepovic, et al.
JCO Precision Oncology|July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol AScott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Cancer Chemotherapy and Pharmacology|May 29, 2025
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Larry V Rubinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
JCO Precision Oncology|January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol HApril K S Salama, Victoria Wang, Erin R Macrae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Pageof 4